<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082133</url>
  </required_header>
  <id_info>
    <org_study_id>Multicenter FA SCT</org_study_id>
    <nct_id>NCT01082133</nct_id>
  </id_info>
  <brief_title>Multicenter Transplant Study for Fanconi Anemia</brief_title>
  <official_title>A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial proposed is a multicenter treatment protocol designed to examine transplant related
      events in patients with Fanconi anemia who lack matched sib donors have severe aplastic
      anemia (SAA), or myelodysplastic syndrome(MDS) or acute myelogenous leukemia (AML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial proposed is a single arm phase II multicenter treatment protocol designed to
      examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival
      following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine
      and ATG (Anti-thymocyte globulin)for the treatment of patients with Fanconi anemia who have
      severe aplastic anemia (SAA), or myelodysplastic syndrome(MDS) or acute myelogenous leukemia
      (AML), lacking HLA-genotypically (HLA = human leukocyte antigen) identical donors using stem
      cell transplants derived from HLA-compatible unrelated donors or HLA haplotype-mismatched
      related donors using Miltenyi's CliniMACS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objectives are: The incidence and quality of engraftment and hematopoietic reconstitution. The incidence of early transplant related mortality The incidence and severity of acute GvHD (graft versus host disease) and chronic GvHD.</measure>
    <time_frame>1-5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of overall survival and disease free survival over time.</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and Miltenyi, CliniMACS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan 0.6-1.0 mg/Kg/dose IV Q 12 hours X4 Doses Fludarabine 35 mg/m2/dose IV once daily X4 Doses Cyclophosphamide 10 mg/Kg/dose IV once daily X4 Doses Anti-thymocyte globulin - Thymoglobulin 2.5 mg/Kg/dose IV daily X4 Doses Miltenyi CliniMACS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Busulfan 0.4-1.0 mg/Kg/dose IV Q 12 hours X4 Doses Fludarabine 35 mg/m2/dose IV once daily X4 Doses Cyclophosphamide 10 mg/Kg/dose IV once daily X4 Doses Anti-thymocyte globulin - Thymoglobulin 2.5 mg/Kg/dose IV daily X4 Doses</description>
    <arm_group_label>Chemotherapy and Miltenyi, CliniMACS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Miltenyi CliniMACS</intervention_name>
    <description>The CliniMACs device (Miltenyi Biotec, Auburn, CA) will be employed for the CD34 selection procedure. It consists of tubing, bags, and a pair of columns, placed at appropriate locations in the Tubing Set to facilitate the cell selection process.</description>
    <arm_group_label>Chemotherapy and Miltenyi, CliniMACS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed Diagnosis of Fanconi Anemia

          -  One of the following:Severe Aplastic Anemia or Severe Single Lineage Cytopenia;
             Myelodysplastic Syndrome; Acute Myelogenous Leukemia

          -  Unrelated and Related Donors

          -  Adequate Physical Function (Cardiac, Hepatic, Renal, Pulmonary)

          -  Available for Long-Term Follow Up

          -  Performance status &gt;= 70%

        Exclusion Criteria:

          -  Co-existing medical problems that increase the risk of transplant

          -  Active CNS (central nervous system) leukemic involvement

          -  Pregnant or Breastfeeding (Females)

          -  Active, Uncontrolled Infection

          -  HIV/HTLV (Human T-lymphotropic virus)Positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stella Davies, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCHMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fanconi Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

